An Open Label Study of the Effects and Safety of Zanubrutinib in NMOSDs Adult Patients

Inclusion Criteria: * Patients must meet the NMOSD diagnostic criteria set by the international NMO Diagnostic Group (IPND) in 2015. * Serum AQP4-IgG positive. * Clinical evidence of at least 2 documented relapse (including first attack) in the last 2 years, with at least 1 relapse within 12 months prior to screening. * Extended Disability Status Scale (EDSS) score ≤7.5 at screening. * Age 18 to 75 years inclusive, weight at least 35 kg at the time of informed consent. * If the patients were using the following baseline treatment for relapse prevention, they must be treated at a steady dose for at least 4 weeks prior to enrollment: * Azathioprine, metecophenol ester and other immunosuppressive agents * Oral corticosteroid (≦30mg/ day prednisone tablet or equivalent dose of other hormones) * (patients or their legal representatives) can provide written informed consent indicating that they understand and agree to comply with the requirements of the study protocol. Exclusion Criteria: * Continuous treatment with strong or moderate CYP3A inhibitors or inducers is required during the study period. Patients were excluded if they had taken a potent or moderate CYP3A inhibitor or inducer within 7 days prior to administration of the study drug (or had stopped taking these drugs for less than 5 half-lives). * Previously treated with BTK inhibitors (e.g., ibrutinib). * Allergic to the study drug or any of the ingredient. * Desease relaps (including first episode) within the pre…